Genentech
1 DNA Way
South San Francisco, California 94080-4990
(650) 225-1000
www.gene.com
|
|
Genentech invites stockholders, security analysts, representatives of
portfolio management firms and other interested parties to contact:
Katherine Littrell, Ph.D., R.N.
Director, Investor Relations
Telephone: (650) 225-1034
Fax: (650) 225-8326
Mailing address at left.
Email: investor.relations@gene.com
|
Genentech is listed on the New York Stock Exchange under the symbol DNA.
|
|
You may obtain a free copy of our annual reports on Form
10-K, quarterly reports on Form 10-Q and current reports on Form 8-K and
amendments to those reports on the day of filing with the Securities and
Exchange Commission on our website on the World Wide Web at www.gene.com,
by calling the Genentech Investor Relations Department at (650) 225-1599,
or by sending an email message to investor.relations@gene.com.
You can also direct requests for literature to our literature request
line at (800) 488-6519.
|
|
Communications concerning transfer requirements, lost certificates and
change of address should be directed to Genentech's transfer agent:
EquiServe Trust Company, N.A.
Post Office Box 43010
Providence, Rhode Island 02940-3010
Telephone: (800) 733-5001
www.equiserve.com
|
|
Ernst & Young LLP
Palo Alto, California
|
|
The annual meeting of stockholders will be held at 10:00 a.m. Pacific
Daylight Time on April 14, 2005, at the Westin Hotel, 1 Old Bayshore Highway,
Millbrae, California. Detailed information about the meeting is contained
in the Notice of Annual Meeting and Proxy Statement sent to each stockholder
of record as of February 14, 2005.
|
|
Genentech has included as Exhibit 31 to its 2004 Annual Report on Form
10-K filed with the Securities and Exchange Commission certificates
of the Chief Executive Officer and Chief Financial Officer of Genentech
certifying the quality of Genentech's public disclosure, and Genentech
submitted to the New York Stock Exchange a certificate of the Chief Executive
Officer certifying that he is not aware of any violation by Genentech
of New York Stock Exchange corporate governance listing standards.
|
